10-Q: United Health Products Reports Q2 2024 Results, Faces FDA Hurdles

Sentiment:

Quarterly Report 13 August 2024 2:00 PM

📋All filings for United Health Products, INC

United Health Products reported a net loss for the second quarter of 2024 and is addressing deficiencies in its FDA application for its hemostatic gauze product.

Delay expectedThe FDA's 'Deficiencies Letter' has paused the 180-day PMA application review period, indicating a delay in the approval process.

Capital raiseThe company has been relying on private placements and unsecured loans from related parties to fund its operations.The company has a common stock purchase agreement with White Lion, which gives the company the right to require White Lion to purchase up to $10,000,000 of the company's common stock.The company issued a $150,000 promissory note payable, which would be repaid by the proceeds of a contemplated future equity investment.

Worse than expectedThe company reported no revenue and a significant net loss, indicating worse than expected financial performance.The FDA's 'Deficiencies Letter' introduces uncertainty and potential delays in the PMA approval process, which is worse than expected.

Summary

United Health Products (UHP) reported its financial results for the second quarter of 2024, showing no revenue and a net loss of $432,021.
The company's operating expenses decreased to $405,177 for the quarter, compared to $475,456 in the same period last year.
UHP is focused on obtaining FDA pre-market approval (PMA) for its HemoStyp product as a Class III device for internal surgical use.
The FDA issued a 'Deficiencies Letter' with approximately 40 comments and requests for additional information on the PMA application.
The company's cash and cash equivalents decreased to $18,754 as of June 30, 2024, from $95,420 at the end of 2023.
UHP has a negative working capital of $2,064,538 as of June 30, 2024.
The company is exploring strategic options, including a potential sale or merger, and commercial partnerships.
UHP has received approximately $3.0 million in proceeds from White Lion to pay for its operations and finalization of its Class III PMA application.

Sentiment

Score: 3

Explanation: The document presents a challenging financial situation with no revenue, significant losses, and a negative working capital. The FDA's 'Deficiencies Letter' adds uncertainty to the regulatory approval process. While the company is exploring strategic options, the overall sentiment is negative due to the financial and regulatory hurdles.

Positives

The net loss decreased for both the three and six months ended June 30, 2024, compared to the same periods in 2023.
Operating expenses decreased for both the three and six months ended June 30, 2024, compared to the same periods in 2023.
The company has submitted its human clinical trial results and other information to the FDA.
UHP is actively exploring strategic options to maximize shareholder value, including potential partnerships and a sale or merger.

Negatives

UHP reported no revenue for the three and six months ended June 30, 2024.
The company has a negative working capital of $2,064,538 as of June 30, 2024.
The FDA issued a 'Deficiencies Letter' requiring additional information on the PMA application, pausing the review period.
The company's cash and cash equivalents have significantly decreased to $18,754 as of June 30, 2024.
There is substantial doubt about the company's ability to continue as a going concern.

Risks

The company's ability to continue as a going concern is dependent on securing additional financing and achieving business goals.
There is no assurance that the FDA will approve the company's Class III PMA application for its HemoStyp product.
The company is subject to extensive regulation by the FDA, and failure to comply could harm the business.
The company is reliant on receiving Premarket Approval (PMA) from the FDA for its HemoStyp product in order to implement its business strategy of targeting the surgical market.
The company may not be able to identify any commercialization candidates or enter into a transaction.

Future Outlook

The company is focused on responding to the FDA's 'Deficiencies Letter' and is evaluating strategic options to grow revenue and profits, including potential partnerships and a sale or merger. The company does not intend to pursue the full commercialization of its products independently nor to remain an independent company in the long term.

Management Comments

Management believes there is an opportunity for HemoStyp products to address unmet needs in several medical applications.
Management is unable to predict if or when a Covered Transaction or Triggering Event under the RSU Agreements governing the restricted stock units will occur.

Industry Context

The company is operating in the competitive hemostatic and wound care market, seeking to gain market share with its HemoStyp product. The company is targeting the Class III surgical market, which has fewer competitors and premium pricing. The company is exploring partnerships with established market participants in the surgical equipment and hemostatic products sectors.

Comparison to Industry Standards

The company's lack of revenue is a significant deviation from industry standards for commercial-stage medical device companies.
The company's reliance on external funding and negative working capital is not typical for established companies in the medical device sector.
The company's focus on obtaining Class III PMA approval is a common strategy for companies seeking to enter the high-value surgical market, but the process is lengthy and uncertain.
The company's exploration of strategic options, including a sale or merger, is a common approach for smaller companies in the medical device sector seeking to maximize shareholder value.

Related Party Transactions

Convertible notes payable to related parties, including Brian Thom and Robert Denser, were amended to extend the maturity date and increase the interest rate.
Accrued compensation was due to the company's officers and management.

Stakeholder Impact

Shareholders face significant risk due to the company's financial condition and the uncertainty of FDA approval.
Employees may be impacted by the company's financial challenges and potential strategic changes.
Customers are not currently impacted as the company has paused commercial activities to focus on the Class III PMA application.
Suppliers may be impacted by the company's financial challenges and potential strategic changes.
Creditors face risk due to the company's negative working capital and reliance on external funding.

Next Steps

The company will respond to the FDA's 'Deficiencies Letter' to address the comments and requests for additional information.
The company will continue to evaluate strategic options, including potential partnerships and a sale or merger.
The company will continue to seek funding to support its operations and PMA application process.

Key Dates

Date	Description
2012	Company received FDA 510(k) approval for HemoStyp for external use.
February 2018	Company submitted PMA application to the FDA for Class III approval.
March 21, 2024	Company submitted results of human clinical trial and other information to the FDA.
June 18, 2024	FDA issued a 'Deficiencies Letter' regarding the PMA application.
June 30, 2024	End of the reporting period for the quarterly results.
August 12, 2024	Number of shares outstanding reported as 248,433,222.
August 13, 2024	Date of the report and certifications.

Keywords

hemostatic gauze, FDA approval, PMA, Class III medical device, HemoStyp, surgical market, regulatory approval, clinical trial, wound care, medical device

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.